CVS Health Reaffirms Previously Announced Full-Year 2024 GAAP Guidance Of At Least $7.06, Adjusted EPS Guidance Of At Least $8.30, Est $8.32
Portfolio Pulse from Benzinga Newsdesk
CVS Health has reaffirmed its full-year 2024 GAAP guidance of at least $7.06 and adjusted EPS guidance of at least $8.30, slightly below the estimated $8.32. The company will also provide updates on recent business trends and initiatives in an upcoming webcast.
March 05, 2024 | 11:16 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
CVS Health reaffirms its 2024 earnings guidance, with a GAAP EPS of at least $7.06 and an adjusted EPS of at least $8.30, slightly under the estimated $8.32.
Reaffirming earnings guidance typically indicates stability in a company's financial outlook, which can reassure investors. However, the adjusted EPS being slightly below estimates might temper expectations. The upcoming webcast could provide further insights, potentially influencing investor sentiment.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100